Patient Name Mr. VISHNU KUMAR SHARMA Lab No 4028352 UHID 40012064 **Collection Date** 23/03/2024 10:20AM 23/03/2024 10:34AM Age/Gender 29 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 23/03/2024 4:06PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9983901206

BIOCHEMISTRY

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE (FASTING)
 97.3
 mg/dl
 71 - 109

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP) 91.1 mg/dl Non – Diabetic: - < 140 mg/dl Pre – Diabetic: - 140-199 mg/dl

Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

THYROID T3 T4 TSH Sample: Serum

T3	1.390	ng/mL	0.970 - 1.690
T4	8.24	ug/dl	5.53 - 11.00
TSH	3.60	μIU/mL	0.40 - 4.05

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Patient Name	Mr. VISHNU KUMAR SHARMA	Lab No	4028352
UHID	40012064	Collection Date	23/03/2024 10:20AM
Age/Gender IP/OP Location	29 Yrs/Male	Receiving Date	23/03/2024 10:34AM
	O-OPD	Report Date	23/03/2024 4:06PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9983901206		

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

 $Interpretation: -The \ determination \ of \ T3 \ is \ utilized \ in \ the diagnosis \ of \ T3-hyperthyroidism \ the \ detection \ of \ early \ stages \ of hyperthyroidism \ and \ for \ indicating \ a \ diagnosis \ of \ thyrotoxicosis \ factitia.$

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation:-The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.29	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.18 L	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.11	mg/dl	0.00 - 0.30	
SGOT	25.0	U/L	0.0 - 40.0	

U/L

g/dl

U/L

0.0 - 41.0

6.6 - 8.7

10.0 - 60.0

 ALBUMIN
 5.0
 g/dl
 3.5 - 5.2

 GLOBULIN
 2.9
 1.8 - 3.6

 ALKALINE PHOSPHATASE
 78
 U/L
 40 - 129

 A/G RATIO
 1.7
 Ratio
 1.5 - 2.5

24.0

26.9

7.9

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

SGPT

GGTP

TOTAL PROTEIN

MBBS | MD | INCHARGE PATHOLOGY

Page: 2 Of 11

Patient NameMr. VISHNU KUMAR SHARMALab No4028352

 UHID
 40012064
 Collection Date
 23/03/2024 10:20AM

 Age/Gender
 29 Yrs/Male
 Receiving Date
 23/03/2024 10:34AM

 IP/OP Location
 O-OPD
 Report Date
 23/03/2024 4:06PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9983901206

BIOCHEMISTRY

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis. nutritional status

cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

TOTAL CHOLESTEROL	209		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	38.4		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	133.4		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	42	mg/dl	10 - 50
TRIGLYCERIDES	208		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl

%

5

RESULT ENTERED BY : SUNIL EHS

CHOLESTEROL/HDL RATIO

Dr. ABHINAY VERMA

Patient Name Mr. VISHNU KUMAR SHARMA Lab No 4028352

UHID 40012064 **Collection Date** 23/03/2024 10:20AM 23/03/2024 10:34AM Age/Gender 29 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 23/03/2024 4:06PM

Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9983901206

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are

synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	28.9	mg/dl	16.60 - 48.50
BUN	13.5	mg/dl	6 - 20
CREATININE	0.92	mg/dl	0.70 - 1.20
SODIUM	140.7	mmol/L	136 - 145
POTASSIUM	4.62	mmol/L	3.50 - 5.50
CHLORIDE	102.2	mmol/L	98 - 107
URIC ACID	5.62	mg/dl	3.4 - 7.0
CALCIUM	10.6 H	mg/dl	8.60 - 10.00

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient NameMr. VISHNU KUMAR SHARMALab No4028352

 UHID
 40012064
 Collection Date
 23/03/2024 10:20AM

 Age/Gender
 29 Yrs/Male
 Receiving Date
 23/03/2024 10:34AM

 IP/OP Location
 O-OPD
 Report Date
 23/03/2024 4:06PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9983901206

BIOCHEMISTRY

CREATININE - SERUM :- Method: -Jaffe method, Interpretation: -To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation: - Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM: - Method: ISE electrode. Interpretation: -Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.

POTASSIUM: - Method: ISE electrode. Interpretation: -Low level: Intake excessive loss formbodydue to diarrhea, womiting

POTASSIUM :- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced

renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

Sample: WHOLE BLOOD EDTA

HBA1C 5.6 % < 5.7% Nondiabetic

5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes

Known Diabetic Patients
< 7 % Excellent Control
7 - 8 % Good Control
> 8 % Poor Control

 ${\tt Method: - Turbidimetric\ inhibition\ immunoassay\ (TINIA)}$

Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 5 Of 11

Patient Name Mr. VISHNU KUMAR SHARMA Lab No 4028352 UHID 40012064 **Collection Date** 23/03/2024 10:20AM 23/03/2024 10:34AM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date IP/OP Location** O-OPD 23/03/2024 4:06PM

Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9983901206

BLOOD BANK INVESTIGATION

Biological Ref. Range Test Name Result Unit

BLOOD GROUPING "O" Rh Positive

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. VISHNU KUMAR SHARMA Lab No 4028352 **Collection Date** 23/03/2024 10:20AM UHID 40012064 23/03/2024 10:34AM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date** O-OPD **IP/OP Location** 23/03/2024 4:06PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9983901206

CLINICAL PATHOLOGY

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	6.5		5.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	0-1	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	1-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. VISHNU KUMAR SHARMA Lab No 4028352 UHID 40012064 **Collection Date** 23/03/2024 10:20AM 23/03/2024 10:34AM Age/Gender 29 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 23/03/2024 4:06PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

9983901206 Mobile No.

CLINICAL PATHOLOGY

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. VISHNU KUMAR SHARMA Lab No 4028352 UHID 40012064 **Collection Date** 23/03/2024 10:20AM 23/03/2024 10:34AM Age/Gender 29 Yrs/Male **Receiving Date** Report Date 23/03/2024 4:06PM **IP/OP Location** O-OPD

Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9983901206

HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Range
CBC (COMPLETE BLOOD COUNT)			Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	15.4	g/dl	13.0 - 17.0
PACKED CELL VOLUME(PCV)	47.9	%	40.0 - 50.0
MCV	96.6 H	fl	82 - 92
MCH	31.0	pg	27 - 32
МСНС	32.2	g/dl	32 - 36
RBC COUNT	4.96	millions/cu.mm	4.50 - 5.50
TLC (TOTAL WBC COUNT)	5.50	10^3/ uL	4 - 10
DIFFERENTIAL LEUCOCYTE COUNT			
NEUTROPHILS	40.9	%	40 - 80
LYMPHOCYTE	45.3 H	%	20 - 40
EOSINOPHILS	6.7 H	%	1 - 6
BASOPHIL	0.7 L	%	1 - 2
MONOCYTES	6.4	%	2 - 10
PLATELET COUNT	3.19	lakh/cumm	1.500 - 4.500

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method:- Calculation bysysmex.
MCH :- Method:- Calculation bysysmex.
MCHC :- Method:- Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS : - Method: Optical detectorblock based on FlowcytometryEOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 10 mm/1st hr 0 - 15

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. VISHNU KUMAR SHARMA Lab No 4028352 23/03/2024 10:20AM UHID 40012064 **Collection Date** 23/03/2024 10:34AM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date** O-OPD **IP/OP Location** 23/03/2024 4:06PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9983901206

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : SUNIL EHS

Mr. VISHNU KUMAR SHARMA **Patient Name** Lab No 4028352 UHID 40012064 **Collection Date** 23/03/2024 10:20AM 23/03/2024 10:34AM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date IP/OP Location** O-OPD 23/03/2024 4:06PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9983901206

X Ray

Test Name Result Unit Biological Ref. Range

X-RAY CHEST P. A. VIEW

Both lung fields are clear.

Both CP angles are clear.

Both hemi-diaphragms are normal in shape and outlines.

Cardiac shadow is withinnormal limits.

Visualized bony thorax is unremarkable.

Correlate clinically &with other related investigations.

End Of Report

RESULT ENTERED BY : SUNIL EHS

Gurer ..

Dr. SURESH KUMAR SAINI

MBBS,MD RADIOLOGIST

Page: 11 Of 11

DEPARTMENT OF CARDIOLOGY

UHID / IP NO	40012064 (8923)	RISNo./Status:	4028352/
Patient Name:	Mr. VISHNU KUMAR SHARMA	Age/Gender:	29 Y/M
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	23/03/2024 9:19AM/ OPSCR23- 24/16489	Scan Date :	
Report Date:	23/03/2024 2:09PM	Company Name:	Final

REFERRAL REASON: HEALTH CHCEKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

Normal Normal								
IVSD	10.7	6-12mm			LVIDS	26.0	20-40mm	
LVIDD	39.3		32-	57mm		LVPWS	16.8	mm
LVPWD	11.7		6-1	2mm		AO	29.1	19-37mm
IVSS	16.8		J	nm		LA	31.6	19-40mm
LVEF	62-64		>	55%		RA	-	mm
	DOPPLEI	R MEA	SUREN	1ENTS &	& CALC	ULATIONS	<u>:</u>	
STRUCTURE	MORPHOLOGY		VELOCITY (m/s)		GRADIENT (mmHg)		REGURGITATION	
MITRAL	NORMAL	Е	0.87	e'		(mining		NIL
VALVE	NORMAL			-		_		1112
VALVE		A	0.70	E/e'	-			
TRICUSPID	NORMAL		Е 0.79		-		NIL	
VALVE		A 0.61						
AORTIC	NORMAL	1.41		-		NIL		
VALVE								
PULMONARY VALVE	NORMAL		0.91		_		NIL	
		I				1		

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

DEPARTMENT OF RADIO DIAGNOSIS

UHID / IP NO	40012064 (8923)	RISNo./Status:	4028352/
Patient Name:	Mr. VISHNU KUMAR SHARMA	Age/Gender:	29 Y/M
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	23/03/2024 9:19AM/ OPSCR23- 24/16489	Scan Date :	
Report Date :	23/03/2024 11:21AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

ULTRASOUND STUDY OF WHOLE ABDOMEN

Liver: Normal in size & echotexture. No obvious significant focal parenchymal mass lesion

noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.

Gall Bladder: Lumen is clear. Wall thickness is normal. CBD is normal.

Pancreas: Normal in size & echotexture.

Spleen: Normal in size & echotexture. No focal lesion seen.

Right Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or

obstructive calculus noted.

Left Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or

obstructive calculus noted.

Urinary Bladder: Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall

thickness is normal.

Prostate: Is normal in size and echotexture.

Others: No significant free fluid is seen in pelvic peritoneal cavity.

IMPRESSION: USG findings are suggestive of

No obvious significant sonographic abnormality noted.

Correlate clinically & with other related investigations.

DR. APOORVA JETWANI

Incharge & Senior Consultant Radiology

MBBS, DMRD, DNB

Reg. No. 26466, 16307